Secondary progressive multiple sclerosis
Therapeutic area
Immunology
Rare disease
No
- Definition
- A multiple sclerosis with a clinical course characterized by a progressive accumulation of neurological disability, independent of relapses, following an initial relapsing-remitting (RR) phase.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Secondary progressive multiple sclerosis
- Therapeutic area
- Immunology
- secondary progressive multiple sclerosis
- SPMS
- secondary-progressive MS
- Disease mechanisms
- Developmental
- Severity
- Severe
- Immunology
- Neurology
- MONDO ID
- MONDO:0000450
- Parent condition
- MONDO:0005284
Related records
Broader conditions (18)
- Autoimmune disease
- Autoimmune disorder of central nervous system
- Autoimmune disorder of the nervous system
- Brain disorder
- Central nervous system disorder
- Chronic progressive multiple sclerosis
- CNS demyelinating autoimmune disease
- Demyelinating disease
- Demyelinating disease of central nervous system
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disorder of development or morphogenesis
- Human disease
- Immune system disorder
- Multiple sclerosis
- Nervous system disorder
- Neurodegenerative disease
Trials (105)
- A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
- A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients
- A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis
- A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis
- A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia
- A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple Sclerosis
- A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
- A Study for Patients With Multiple Sclerosis
- A Study for Patients With Secondary Progressive Multiple Sclerosis
- A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis
- A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
- A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
- A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
- A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS
- A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis
- A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
- Acceptance Based Telephone Support When Transitioning to SPMS
- ACTH in Progressive Forms of MS
- AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis
Approved drugs (2)
- Ocrelizumab
- Siponimod fumaric acid
Drugs in development (28)
- Amiloride Phase 2
- Baminercept Phase 1
- Corticotropin Phase 2
- Dalfampridine Phase 3
- Dirucotide Phase 3
- Estriol Phase 2
- Evruleucel Phase 1
- Ferumoxytol Early phase 1
- Fluoxetine Phase 2
- Foralumab Phase 2
- Gadoteridol Early phase 1
- Glatiramer acetate Phase 2
- Lamotrigine Phase 2
- Lipoic acid, alpha Phase 2
- Metformin Early phase 1
- Metformin hydrochloride Phase 2
- Methylprednisolone sodium succinate Phase 3
- Mitoxantrone Phase 3
- Natalizumab Phase 3
- Norethindrone Phase 2
Other linked drugs (1)
- Ofatumumab